Expanded Access Use of Cemiplimab in Patients With Solid Tumors

Conditions

• Basal Cell Carcinoma (BCC)
• Cutaneous Squamous Cell Carcinoma (CSCC)
• Non-Small Cell Lung Cancer (NSCLC)

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Cemiplimab — DRUG

Study Details

Provide expanded access of cemiplimab in patients with solid tumors

Key Dates

Status verified

Nov 2025

Related Studies

• Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
  PHASE1/PHASE2 · Recruiting · Olivera Finn · Pittsburgh, Pennsylvania
• ROSE for Improved Molecular Marker Testing Via EBUS
  Enrolling By Invitation · Johns Hopkins University · Chicago, Illinois
• A Study of NX-1607 in Adults With Advanced Malignancies
  PHASE1 · Recruiting · Nurix Therapeutics, Inc. · Duarte, California
• Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
  PHASE1 · Recruiting · Exelixis · Phoenix, Arizona